Medication therapy in aneurysmatic cerebral haemorrhage.
- Conditions
- AneurysmSubarachnoid haemorrhage/hemorrhageTranexamic acid, CyklokapronAcetylsalicylic acid, AspirinAneurysmaSubarachnoidale bloedingTranexaminezuurAcetylsalicylzuur, Aspirine
- Registration Number
- NL-OMON27006
- Lead Sponsor
- Germans, M.R.Coert, B.A.
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 300
Inclusion Criteria
1. Aneurysmatic SAH less than 48 hours ago;
2. Age 18 years and older;
Exclusion Criteria
1. Presence of deep vein thrombosis;
2. History of blood coagulation disorder;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Modified Rankin Scale.
- Secondary Outcome Measures
Name Time Method 1. In hospital possible or definite rebleed and interval with first haemorrhage;<br /><br>2. Rebleed during endovascular or surgical treatment;<br /><br>3. Thromboembolic events during endovascular treatment;<br /><br>4. (Micro)infarctions on MR-imaging after treatment and after 6 months;<br /><br>5. Hemorrhagic complications (intra and extracranial);<br /><br>6. Extracranial thrombosis;<br /><br>7. Treatment for hydrocephalus (lumbar puncture, lumbar or ventricular drainage);<br /><br>8. Hemorrhagic complications with neurological deficit after placement of an extraventricular drain.<br>